News
18h
ABP News on MSNBeyond The Hype — What India Must Know About Weight-Loss DrugsWeight-loss injections like semaglutide are trending in India, but are they safe? Know the science, risks, and why expert ...
Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...
Miracle’ drugs used for weight-loss like Semaglutide and Tirzepatide—better known by their brand names Ozempic and ...
Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.
14h
News-Medical.Net on MSNWhich GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answersResearchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...
10h
Vietnam Investment Review on MSNAscletis Begins Dosing in U S Phase IIa Study for Monthly GLP 1R Obesity DrugAscletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in its U.S. 12-week ...
"We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate ...
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...
CBL-514, Caliway's first-in-class lipolysis drug candidate, has been granted clearance from the U.S. FDA to proceed with SUPREME-01, a global, ...
These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...
CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.
There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results